Dobuject

New Zealand - English - Medsafe (Medicines Safety Authority)

Buy It Now

Active ingredient:
Dobutamine hydrochloride 56.05 mg equivalent to Dobutamine 50 mg
Available from:
Mylan New Zealand Ltd
INN (International Name):
Dobutamine hydrochloride 56.05 mg (equivalent to Dobutamine 50 mg)
Dosage:
50 mg/mL
Pharmaceutical form:
Concentrate for infusion
Composition:
Active: Dobutamine hydrochloride 56.05 mg equivalent to Dobutamine 50 mg Excipient: Ascorbic acid Water for injection
Units in package:
Ampoule, glass, type 1 borosillicate glass, 5x5 mL, 5 dose units
Class:
Prescription
Prescription type:
Prescription
Manufactured by:
Recordati SpA
Therapeutic indications:
Dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. Dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. Conditions which may precipitate such situations include the following hypoperfusion states: Initially cardiac in origin A. Acute heart failure 1. Acute myocardial infarction 2. Cardiogenic shock 3. Following cardiac surgery 4. Medicine-induced depression of cardiac contractility such as that which occurs in excessive beta-adrenergic receptor blockade. B. Chronic heart failure 1. Acute decompensation of chronic congestive heart failure 2. Temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vas
Product summary:
Package - Contents - Shelf Life: Ampoule, glass, type 1 borosillicate glass, 5x5 mL - 5 dose units - 24 months from date of manufacture stored at or below 25°C protect from light
Authorization number:
TT50-8224
Authorization date:
2008-10-06

Similar products

Search alerts related to this product

Share this information